KT-253
Phase
Phase1Study status
CompletedView details
Kymera Therapeutics, Inc.
IndicationMyeloid Malignancies; Acute Lymphocytic Leukemia; Lymphomas; Advanced Solid Tumors
Actual study completion2024-12-18
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
No verified development in tracked sources.
Next verified event · Clinical readout window
Announced Oct 29, 2026 · Announced window
Official announcementIn October 2026, the last patient received their final dose and completed the week 16 visit in the KT-621 BROADEN2 Phase 2b clinical trial in patients with moderate to severe AD. The Company plans to report topline data by year-end 2026. Subject to discussions with regulators, the Company expects to initiate the first Phase 3 trial in AD by mid-2027.
Clinical readout window
moderate to severe eosinophilic asthma
Phase 2b
Announced Oct 29, 2026 · Announced window
Official announcementEnrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients with moderate to severe eosinophilic asthma, with topline data expected to be reported in late 2027.
6 programs · 11 verified studies
| Company | Drug | Indication | Phase | Study status | Timing | Registry |
|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics, Inc. | KT-253 | Myeloid Malignancies; Acute Lymphocytic Leukemia; Lymphomas; Advanced Solid Tumors | Phase1 | Completed | Actual study completion2024-12-18 | NCT05775406 |
| KYMR Kymera Therapeutics, Inc. | KT-333 | Non Hodgkin Lymphoma (NHL); Peripheral T-cell Lymphoma (PTCL); Cutaneous T-Cell Lymphoma (CTCL); Large Granular Lymphocytic Leukemia (LGL-L); T-cell Prolymphocytic Leukemia (T-PLL); Solid Tumors | Phase1 | Completed | Actual study completion2025-03-03 | NCT05225584 |
| KYMR Kymera Therapeutics, Inc. | KT-413 | Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; DLBCL; MYD88 Gene Mutation | Phase1 | Completed | Actual study completion2023-07-28 | NCT05233033 |
| KYMR Kymera Therapeutics, Inc. | KT-474 | Healthy Volunteer; Atopic Dermatitis; Hidradenitis Suppurativa | Phase1 | Completed | Actual study completion2022-10-20 | NCT04772885 |
| KYMR Kymera Therapeutics, Inc. | KT-579 | Healthy Participants | Phase1 | Completed | Actual study completion2026-08-22 | NCT07412288 |
| KYMR Kymera Therapeutics, Inc. | KT-621 | Healthy Participants Study | Phase1 | Completed | Actual study completion2025-04-23 | NCT06673667 |
| KYMR Kymera Therapeutics, Inc. | KT-621 | Atopic Dermatitis | Phase1 | Completed | Actual study completion2025-11-10 | NCT06945458 |
| KYMR Kymera Therapeutics, Inc. | KT-621 | Atopic Dermatitis | Phase2 | Active not recruiting | Estimated study completion2028-06 Announced catalyst timingBy year-end 2026 | NCT07217015 |
| KYMR Kymera Therapeutics, Inc. | KT-621 | Eosinophilic Asthma | Phase2 | Recruiting | Estimated study completion2027-12 | NCT07323654 |
| KYMR Kymera Therapeutics, Inc. | KT-621 | Asthma (Diagnosis) | Phase2 | Recruiting | Estimated study completion2028-12 | NCT07677059 |
Phase
Phase1Study status
CompletedKymera Therapeutics, Inc.
IndicationMyeloid Malignancies; Acute Lymphocytic Leukemia; Lymphomas; Advanced Solid Tumors
Actual study completion2024-12-18
Phase
Phase1Study status
CompletedKymera Therapeutics, Inc.
IndicationNon Hodgkin Lymphoma (NHL); Peripheral T-cell Lymphoma (PTCL); Cutaneous T-Cell Lymphoma (CTCL); Large Granular Lymphocytic Leukemia (LGL-L); T-cell Prolymphocytic Leukemia (T-PLL); Solid Tumors
Actual study completion2025-03-03
Phase
Phase1Study status
CompletedKymera Therapeutics, Inc.
IndicationNon Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; DLBCL; MYD88 Gene Mutation
Actual study completion2023-07-28
Phase
Phase1Study status
CompletedKymera Therapeutics, Inc.
IndicationHealthy Volunteer; Atopic Dermatitis; Hidradenitis Suppurativa
Actual study completion2022-10-20
Phase
Phase1Study status
CompletedKymera Therapeutics, Inc.
IndicationHealthy Participants
Actual study completion2026-08-22
Phase
Phase1Study status
CompletedKymera Therapeutics, Inc.
IndicationHealthy Participants Study
Actual study completion2025-04-23
Phase
Phase1Study status
CompletedKymera Therapeutics, Inc.
IndicationAtopic Dermatitis
Actual study completion2025-11-10
Phase
Phase2Study status
Active not recruitingKymera Therapeutics, Inc.
IndicationAtopic Dermatitis
Estimated study completion2028-06
Announced catalyst timingBy year-end 2026
Phase
Phase2Study status
RecruitingKymera Therapeutics, Inc.
IndicationEosinophilic Asthma
Estimated study completion2027-12
Phase
Phase2Study status
RecruitingKymera Therapeutics, Inc.
IndicationAsthma (Diagnosis)
Estimated study completion2028-12
3 unverified sponsor matches remain unlinked.
No verified developments in tracked sources.